Addyi Health Fact Sheet

  What is Flibanserin (Addyi)? Flibanserin (brand name: Addyi) is the first drug approved by the U.S. Food and Drug Administration (FDA) to treat lack of sexual desire (Hypoactive Sexual Desire Disorder) in premenopausal women.  Although the drug is ineffective and potentially dangerous, the agency approved it in 2015 over the objections of the NWHN and … Continued

Health Advocates Issue One-Year Report Card on Addyi, the Female Libido Drug

FOR IMMEDIATE RELEASE Contact: Shaniqua Seth at or 202.682-2640, ext. 225 WASHINGTON, DC – August 18th marks the one-year anniversary of the Food and Drug Administration’s (FDA) approval of flibanserin (brand name: Addyi), the so-called “female Viagra” pill. In light of recent developments, the National Women’s Health Network (NWHN) has issued a one-year report … Continued

Addyi Report: One Year Later!

One year ago today, the FDA buckled to pressure from a savvy astroturf campaign and approved the female libido drug flibanserin (brand name: Addyi). In response, we launched the “Pass on the Pink Pill – Or Pass Out” campaign to warn women of the marginal benefits and serious side effects of the “pink pill”—complications like … Continued

Addyi 1 Year Later: What’s the Score?

Click image to download PDF of the report card Report Card References 1 – Addyi’s FDA Warning Addyi’s life-threatening side effects were so grave that they warranted the strictest possible warning by the FDA—a “black box warning.” Those side effects include severe, sudden drops in blood pressure that can lead to loss of consciousness for … Continued

Flibanserin Update: Health and Safety Concerns Continue to be Profound

On Monday, JAMA Internal Medicine published a systematic review evaluating the safety and efficacy of flibanserin, a drug purported to treat Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. Unsurprisingly, the researchers reported that flibanserin’s benefits are “are marginal, particularly when taking into account the concurrent occurrence of adverse events.” Further, the researchers reported “the … Continued

Warning of marginal benefits and serious side effects as drug sales begin

FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson and Susan Wood: Sarah Courtney at or 917-913-1994   “PASS ON THE PINK PILL – OR PASS OUT!” Health Advocates Issue Emergency Alert on Addyi:  The New Sex Drug for Women WASHINGTON, DC – The consumer advocacy group National Women’s Health Network (NWHN) today issued its first ever … Continued

Consumer Alert — Pass on the Pink Pill Or Pass Out

EMERGENCY WOMEN’S HEALTH ALERT ON ADDYI The New Sex Drug for Women The National Women’s Health Network is warning all women about the health risks of the new “pink pill” – known as flibanserin and branded as Addyi – alleged to boost female libido. Rather than rely on drug company marketing, NWHN recommends that women … Continued

Flibanserin: the FDA’s Approval is Bad Science and Bad Precedent

This year, the Food and Drug Administration (FDA) made history — for all the wrong reasons. After a five-year battle for approval, on August 18th, the agency succumbed to a relentless and clever public relations campaign and approved flibanserin, the first drug to treat hypoactive sexual desire disorder (HSDD) in women. That means that, as … Continued

Addyi Hits the Market. Learn the Truth!

It’s official – Addyi is on the market. As of today, the drug is available by prescription. The FDA approved it for premenopausal women who have lost the desire for sex, for no reason (Hypoactive Sexual Desire Disorder). By now, you have probably heard a lot about Addyi and may even know someone considering trying … Continued

The National Women’s Health Network Continues to Express Deep Concern Over Addyi’s Safety

FOR IMMEDIATE RELEASE  Contact:   Christina Cherel at or (202) 682-2640   Washington, D.C. – Tomorrow, the first FDA-approved drug to treat hypoactive sexual desire disorder (HSDD) in premenopausal women will be available by prescription. The National Women’s Health Network (“the Network”) remains deeply concerned over the unanswered questions regarding Addyi’s interaction with alcohol and the drug’s … Continued